These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 34990700)

  • 1. Hydroxyapatite-binding albumin nanoclusters for enhancing bone tumor chemotherapy.
    Kang NW; Lee JY; Kim DD
    J Control Release; 2022 Feb; 342():111-121. PubMed ID: 34990700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the therapeutic efficacy of the MAP regimen using thiamine pyrophosphate-decorated albumin nanoclusters in osteosarcoma treatment.
    Yoo SY; Mun YH; Kang NW; Koo JM; Lee DH; Yoo JH; Lee SM; Koh S; Park JC; Kim T; Shin EK; Lee HS; Sim J; Kang KW; Kim SK; Cho CW; Kim MG; Kim DD; Lee JY
    Bioeng Transl Med; 2023 Nov; 8(6):e10472. PubMed ID: 38023714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone tumor-homing nanotherapeutics for prolonged retention in tumor microenvironment and facilitated apoptotic process
    Kang NW; Visetvichaporn V; Nguyen DT; Shin EK; Kim D; Kim MJ; Yoo SY; Lee JY; Kim DD
    Mater Today Bio; 2023 Apr; 19():100591. PubMed ID: 36873733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
    Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
    J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
    Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
    Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redox-responsive mesoporous selenium delivery of doxorubicin targets MCF-7 cells and synergistically enhances its anti-tumor activity.
    Zhao S; Yu Q; Pan J; Zhou Y; Cao C; Ouyang JM; Liu J
    Acta Biomater; 2017 May; 54():294-306. PubMed ID: 28267598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo.
    Zheng K; Li R; Zhou X; Hu P; Zhang Y; Huang Y; Chen Z; Huang M
    Int J Nanomedicine; 2015; 10():5327-42. PubMed ID: 26346331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis.
    Ferreira Ddos S; Faria SD; Lopes SC; Teixeira CS; Malachias A; Magalhães-Paniago R; de Souza Filho JD; Oliveira BL; Guimarães AR; Caravan P; Ferreira LA; Alves RJ; Oliveira MC
    Int J Nanomedicine; 2016; 11():3737-51. PubMed ID: 27563241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.
    Qiu R; Sun D; Bai Y; Li J; Wang L
    Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Therapeutic Effect of Human Serum Albumin Dimer-Doxorubicin Complex against Human Pancreatic Tumors.
    Kinoshita R; Ishima Y; Chuang VTG; Watanabe H; Shimizu T; Ando H; Okuhira K; Otagiri M; Ishida T; Maruyama T
    Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oleanolic acid-conjugated human serum albumin nanoparticles encapsulating doxorubicin as synergistic combination chemotherapy in oropharyngeal carcinoma and melanoma.
    Kumbham S; Paul M; Itoo A; Ghosh B; Biswas S
    Int J Pharm; 2022 Feb; 614():121479. PubMed ID: 35041911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-targeted intracellular delivery of anticancer drugs through the mannose-6-phosphate/insulin-like growth factor II receptor.
    Prakash J; Beljaars L; Harapanahalli AK; Zeinstra-Smith M; de Jager-Krikken A; Hessing M; Steen H; Poelstra K
    Int J Cancer; 2010 Apr; 126(8):1966-1981. PubMed ID: 19795464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained and controlled delivery of doxorubicin from an in-situ setting biphasic hydroxyapatite carrier for local treatment of a highly proliferative human osteosarcoma.
    Liu Y; Raina DB; Sebastian S; Nagesh H; Isaksson H; Engellau J; Lidgren L; Tägil M
    Acta Biomater; 2021 Sep; 131():555-571. PubMed ID: 34271171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted osteosarcoma chemotherapy using RGD peptide-installed doxorubicin-loaded biodegradable polymeric micelle.
    Fang Z; Sun Y; Xiao H; Li P; Liu M; Ding F; Kan W; Miao R
    Biomed Pharmacother; 2017 Jan; 85():160-168. PubMed ID: 27930982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer.
    Ye WL; Zhao YP; Li HQ; Na R; Li F; Mei QB; Zhao MG; Zhou SY
    Sci Rep; 2015 Sep; 5():14614. PubMed ID: 26419507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.
    Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS
    J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-triggered drug-release vehicles for synergistic cancer therapy.
    Tu TY; Yang SJ; Tsai MH; Wang CH; Lee SY; Young TH; Shieh MJ
    Colloids Surf B Biointerfaces; 2019 Jan; 173():788-797. PubMed ID: 30384276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Actively targeted delivery of doxorubicin to bone metastases by a pH-sensitive conjugation.
    Ye WL; Zhao YP; Na R; Li F; Mei QB; Zhao MG; Zhou SY
    J Pharm Sci; 2015 Jul; 104(7):2293-303. PubMed ID: 25980534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tumor environment responsive doxorubicin-loaded nanoparticle for targeted cancer therapy.
    Zhu Q; Jia L; Gao Z; Wang C; Jiang H; Zhang J; Dong L
    Mol Pharm; 2014 Oct; 11(10):3269-78. PubMed ID: 24735448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma.
    Li TF; Li K; Zhang Q; Wang C; Yue Y; Chen Z; Yuan SJ; Liu X; Wen Y; Han M; Komatsu N; Xu YH; Zhao L; Chen X
    Biomaterials; 2018 Oct; 181():35-52. PubMed ID: 30071380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.